Celularity (NASDAQ:CELU) Shares Down 0.5% – Here’s What Happened

Celularity Inc. (NASDAQ:CELU) traded down 0.5% during mid-day trading on Friday . The company traded as low as $2.10 and last traded at $2.16. 22,452 shares were traded during mid-day trading, a decline of 72% from the average session volume of 78,825 shares. The stock had previously closed at $2.17.

Celularity Trading Down 0.5 %

The company has a 50-day moving average of $2.39 and a 200-day moving average of $2.65.

Celularity (NASDAQ:CELU) last announced its quarterly earnings results on Wednesday, October 16th. The company reported ($1.03) earnings per share (EPS) for the quarter. The firm had revenue of $14.68 million during the quarter. Celularity had a negative return on equity of 119.53% and a negative net margin of 72.72%.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.